enGene (ENGN) Projected to Post Earnings on Thursday

enGene (NASDAQ:ENGN) is expected to issue its Q4 2025 results before the market opens on Thursday, December 18th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, December 19, 2025 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, September 11th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Stock Performance

enGene stock opened at $8.01 on Thursday. The firm has a fifty day simple moving average of $7.81 and a two-hundred day simple moving average of $5.53. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.09. enGene has a twelve month low of $2.65 and a twelve month high of $11.14. The company has a market capitalization of $517.29 million, a PE ratio of -4.22 and a beta of -0.28.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ENGN shares. UBS Group increased their target price on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, November 12th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective (up previously from $30.00) on shares of enGene in a research note on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Wednesday, November 12th. Citizens Jmp increased their price target on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. Finally, Raymond James Financial upgraded shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.38.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC purchased a new stake in shares of enGene in the 2nd quarter worth about $36,000. Paloma Partners Management Co purchased a new stake in enGene in the second quarter worth about $38,000. Raymond James Financial Inc. boosted its position in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares in the last quarter. Citadel Advisors LLC boosted its position in enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after acquiring an additional 35,327 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares during the period. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.